Search Results - "Pieczonka, Christopher. M"

Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer by Freedland, Stephen J., de Almeida Luz, Murilo, De Giorgi, Ugo, Gleave, Martin, Gotto, Geoffrey T., Pieczonka, Christopher M., Haas, Gabriel P., Kim, Choung-Soo, Ramirez-Backhaus, Miguel, Rannikko, Antti, Tarazi, Jamal, Sridharan, Swetha, Sugg, Jennifer, Tang, Yiyun, Tutrone, Ronald F., Venugopal, Balaji, Villers, Arnauld, Woo, Henry H., Zohren, Fabian, Shore, Neal D.

“…In patients with high-risk biochemically recurrent prostate cancer, treatment with enzalutamide and leuprolide improved metastasis-free survival as compared…”
Get full text

A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer by Parekh, Dipen J, Punnen, Sanoj, Sjoberg, Daniel D, Asroff, Scott W, Bailen, James L, Cochran, James S, Concepcion, Raoul, David, Richard D, Deck, Kenneth B, Dumbadze, Igor, Gambla, Michael, Grable, Michael S, Henderson, Ralph J, Karsh, Lawrence, Krisch, Evan B, Langford, Timothy D, Lin, Daniel W, McGee, Shawn M, Munoz, John J, Pieczonka, Christopher M, Rieger-Christ, Kimberley, Saltzstein, Daniel R, Scott, John W, Shore, Neal D, Sieber, Paul R, Waldmann, Todd M, Wolk, Fredrick N, Zappala, Stephen M

“…Abstract Background The 4Kscore combines measurement of four kallikreins in blood with clinical information as a measure of the probability of significant…”
Get full text

Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data by Karsh, Lawrence I., Gross, Eric T., Pieczonka, Christopher M., Aliotta, Philip J., Skomra, Christopher J., Ponsky, Lee E., Nieh, Peter T., Han, Misop, Hamstra, Daniel A., Shore, Neal D.

“…To provide an update on SpaceOAR System, a Food and Drug Administration–approved hydrogel indicated to create distance between the prostate and the rectum…”
Get full text

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry by Sartor, Oliver, Armstrong, Andrew J., Ahaghotu, Chiledum, McLeod, David G., Cooperberg, Matthew R., Penson, David F., Kantoff, Philip W., Vogelzang, Nicholas J., Hussain, Arif, Pieczonka, Christopher M., Shore, Neal D., Quinn, David I., Small, Eric J., Heath, Elisabeth I., Tutrone, Ronald F., Schellhammer, Paul F., Harmon, Matthew, Chang, Nancy N., Sheikh, Nadeem A., Brown, Bruce, Freedland, Stephen J., Higano, Celestia S.

“…Purpose African Americans experience greater prostate cancer risk and mortality than do Caucasians. An analysis of pooled phase III data suggested differences…”
Get full text

Real‐world outcomes of sipuleucel‐T treatment in PROCEED, a prospective registry of men with metastatic castration‐resistant prostate cancer by Higano, Celestia S., Armstrong, Andrew J., Sartor, A. Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.

“…Background The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated…”
Get full text

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials by Antonarakis, Emmanuel S, Subudhi, Sumit K, Pieczonka, Christopher M, Karsh, Lawrence I, Quinn, David I, Hafron, Jason M, Wilfehrt, Helen M, Harmon, Matthew, Sheikh, Nadeem A, Shore, Neal D, Petrylak, Daniel P

“…We present long-term outcomes from 2 randomized studies [STAMP (with abiraterone, NCT01487863) and STRIDE (with enzalutamide, NCT01981122)] that were performed…”
Get full text

Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN by Shen, John, Chowdhury, Simon, Agarwal, Neeraj, Karsh, Lawrence I., Oudard, Stéphane, Gartrell, Benjamin A., Feyerabend, Susan, Saad, Fred, Pieczonka, Christopher M., Chi, Kim N., Brookman-May, Sabine D., Rooney, Brendan, Bhaumik, Amitabha, McCarthy, Sharon A., Bevans, Katherine B., Mundle, Suneel D., Small, Eric J., Smith, Matthew R., Graff, Julie N.

“…Background Apalutamide plus androgen-deprivation therapy (ADT) improved outcomes in metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic…”
Get full text

Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer by Shore, Neal D, Polikarpov, Dmitry M, Pieczonka, Christopher M, Henderson, R Jonathan, Bailen, James L, Saltzstein, Daniel R, Concepcion, Raoul S, Beebe-Dimmer, Jennifer L, Ruterbusch, Julie J, Levin, Rachel A, Wissmueller, Sandra, Le, Thao Ho, Gillatt, David A, Chan, Daniel W, Deng, Niantao, Siddireddy, Jaya Sowjanya, Lu, Yanling, Campbell, Douglas H, Walsh, Bradley J

“…There is a clinical need to identify patients with an elevated PSA who would benefit from prostate biopsy due to the presence of clinically significant…”
Get full text

Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data by Higano, Celestia S., Armstrong, Andrew J., Sartor, Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.

Get full text

Development and evaluation of the MiCheck test for aggressive prostate cancer by Shore, Neal D., Pieczonka, Christopher M., Henderson, R. Jonathan, Bailen, James L., Saltzstein, Daniel R., Concepcion, Raoul S., Beebe-Dimmer, Jennifer L., Ruterbusch, Julie J., Levin, Rachel A., Wissmueller, Sandra, Le, Thao Ho, Gillatt, David, Chan, Daniel W., Campbell, Douglas H., Walsh, Bradley J.

“…•MiCheck test is a blood test developed to detect aggressive prostate cancer.•Uses an algorithm containing clinical factors and soluble analytes to give a risk…”
Get full text

A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial by Shore, Neal D., Pieczonka, Christopher M., Henderson, R. Jonathan, Bailen, James L., Saltzstein, Daniel R., Concepcion, Raoul S., Beebe-Dimmer, Jennifer L., Ruterbusch, Julie J., Le, Thao Ho, Levin, Rachel A., Wissmueller, Sandra, Prah, Philip, Borotkanics, Robert, Paivanas, Thomas A., van Breda, Arletta, Campbell, Douglas H., Walsh, Bradley J.

“…•Contemporary US trial collecting subjects presenting for biopsy due to elevated prostate specific antigen (PSA).•Confirms trend towards more subjects…”
Get full text

Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients by Pieczonka, Christopher M, Twardowski, Przemyslaw, Renzulli, 2nd, Joseph, Hafron, Jason, Boldt-Houle, Deborah M, Atkinson, Stuart, Eggener, Scott

“…Evidence suggests lower nadir testosterone levels during the first year of androgen deprivation therapy improve advanced prostate cancer clinical outcomes. We…”
Get full text

Associated Medical Professionals, Syracuse, NY by Albala, David M, Mariados, Neil F, Pieczonka, Christopher M

Get full text

Hydrogel Spacer Application Technique, Patient Tolerance and Impact on Prostate Intensity Modulated Radiation Therapy: Results from a Prospective, Multicenter, Pivotal Randomized Controlled Trial by Pieczonka, Christopher M, Mariados, Neil, Sylvester, John E, Karsh, Lawrence I, Hudes, Richard S, Beyer, David C, Kurtzman, Steven M, Bogart, Jeffrey A

“…INTRODUCTIONWe evaluate the safety, tolerability and impact on therapy of an absorbable hydrogel perirectal spacer (SpaceOAR® system) designed to reduce the…”
Get full text

MP41-08 UTILIZING PATIENT-REPORTED OUTCOMES TO ASSESS THE IMPACT OF UNIVERSAL GERMLINE GENETIC TESTING FOR PROSTATE CANCER by Shore, Neal, Pieczonka, Christopher M., Heron, Sean, Gazi, Mukaram, Cahn, David J., Belkoff, Laurence, Berger, Aaron D., Mazzarella, Brian, Morris, David, Veys, Joseph, Bevan-Thomas, Richard, Engelman, Alexander, Dato, Paul, Cornell, Robert, Wise, David R., Hardwick, Mary Kay, Hatchell, Kathryn E., Heald, Brandie, Nussbaum, Robert L., Nielsen, Sarah M., Esplin, Edward D.

Get full text

LONGITUDINAL CHANGES IN PATIENT-REPORTED OUTCOMES (PROs) IN PATIENTS WITH HIGH-RISK BIOCHEMICALLY RECURRENT (BCR) NONMETASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) FROM THE EMBARK STUDY by Freedland, Stephen J., Gleave, Martin, De Giorgi, Ugo, Rannikko, Antti, Pieczonka, Christopher M., Tutrone Jr, Ronald F., Venugopal, Balaji, Woo, Henry, Backhaus, Miguel Ramirez, Supiot, Stephane, Lantz, Anna, Ganguli, Arijit, Ivanova, Jasmina, Kral, Pavol, Huang, Shu-Pin, Saad, Fred, Shore, Neal

“…In the phase 3 EMBARK trial (NCT02319837), enzalutamide (ENZA)+leuprolide acetate (L) and ENZA alone significantly delayed metastasis-free survival (MFS) vs…”
Get full text

A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC) by Ross, Ashley, Armstrong, Andrew J., Pieczonka, Christopher M, Bailen, James L., Tutrone, Ronald F., Cooperberg, Matthew R., Pavlovich, Christian P., Renzulli, Joseph F., Haynes, Heather, Sheikh, Nadeem Anwar, Shore, Neal D.

“…Abstract only 321 Background: Sip-T is an FDA approved, autologous cellular immunotherapy for mCRPC, manufactured by activating peripheral blood mononuclear…”
Get full text

Potential underestimation of cerebrovascular events in the Provenge Registry for the Observation, Collection, and Evaluation of Experience Data – A Response by Higano, Celestia S., Armstrong, Andrew J., Sartor, Oliver, Vogelzang, Nicholas J., Kantoff, Philip W., McLeod, David G., Pieczonka, Christopher M., Penson, David F., Shore, Neal D., Vacirca, Jeffrey, Concepcion, Raoul S., Tutrone, Ronald F., Nordquist, Luke T., Quinn, David I., Kassabian, Vahan, Scholz, Mark C., Harmon, Matt, Tyler, Robert C., Chang, Nancy N., Tang, Hong, Cooperberg, Matthew R.

Get full text

Abstract D084: Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC)—final PROCEED analysis by Sartor, Oliver, Armstrong, Andrew J, Ahaghotu, Chiledum, McLeod, David G, Cooperberg, Matthew R, Penson, David F, Kantoff, Philip W, Vogelzang, Nicholas J, Hussain, Arif, Pieczonka, Christopher. M, Shore, Neal D, Quinn, David I, Heath, Elisabeth I, Tutrone, Ronald F, Schellhammer, Paul F, Harmon, Matthew, Chang, Nancy N, Freedland, Stephen J, Higano, Celestia S

“…BACKGROUND: Prostate cancer risk and mortality are higher in AAs versus CAUs. Post-hoc analyses of pooled Phase 3 data (n = 737) suggested substantial OS…”
Get full text

PD14-06 SIPULEUCEL-T (SIP-T) WITH ENZALUTAMIDE (ENZ) (STRIDE): CLINICAL OUTCOMES IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) BY BASELINE (BL) PROSTATE-SPECIFIC ANTIGEN (PSA) QUARTILES by Corman, John, Petrylak, Daniel P, Drake, Charles G, Pieczonka, Christopher M, Karsh, Lawrence I, Concepcion, Raoul S, Garcia, Jorge A, Dunshee, Curtis J, Van Mouwerik, Tim, Tyler, Robert C, Chang, Nancy N, Quinn, David I

Get full text